Drug General Information
Drug ID
D0I1BQ
Former ID
DCL000842
Drug Name
IL-18BP
Indication B-cell non-hodgkin's lymphoma; Rheumatoid arthritis [ICD9: 200, 202, 202.8, 710-719, 714; ICD10:C81-C86, C82-C85, M00-M25, M05-M06] Discontinued in Phase 1 [547123]
Company
Yeda; Merck Serono
Target and Pathway
Target(s) Interleukin-18 Target Info Binder [536651]
KEGG Pathway Cytokine-cytokine receptor interaction
NOD-like receptor signaling pathway
Cytosolic DNA-sensing pathway
Salmonella infection
Legionellosis
African trypanosomiasis
Malaria
Tuberculosis
Influenza A
Inflammatory bowel disease (IBD)
Rheumatoid arthritis
NetPath Pathway IL4 Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Toll receptor signaling pathway
Pathway Interaction Database IL27-mediated signaling events
IL12-mediated signaling events
IL23-mediated signaling events
Cellular roles of Anthrax toxin
IL12 signaling mediated by STAT4
Reactome Interleukin-1 processing
WikiPathways Hypertrophy Model
IL1 and megakaryotyces in obesity
Corticotropin-releasing hormone
NOD pathway
References
Ref 547123Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013227)
Ref 536651Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.